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BACKGROUND/PURPOSE: The number of community-onset bacteremic urinary tract infections (UTIs) 
caused by Escherichia coli and Klebsiella pneumoniae is increasing. However, the impact of extended-spectrum 
β-lactamase (ESBL)-producing E. coli and K. pneumoniae (ESBL-EK) on bacteremic UTI outcomes is unknown. 
The aim of this study was to retrospectively analyze the impact of ESBL-EK on community-onset bacteremic 
UTIs.
METHODS: Of the 58 patients enrolled, 12 suffered from ESBL-EK-caused community-onset bactere-
mic UTIs. Patients were categorized into ESBL (n = 12) and non-ESBL (n = 46) groups. Diagnosis was based 
on findings of concurrent bacteremia and bacteriuria caused by the same pathogen on admission.
RESULTS: The ESBL group had significantly more male patients (66.7% vs. 23.9%; p = 0.005), indwelling 
urinary catheters (41.7% vs. 6.5%; p = 0.002), patients admitted from other healthcare facilities (50.0% vs. 
8.7%; p = 0.001), and patients with higher Acute Physiology and Chronic Health Evaluation II scores 
(23.3 ± 7.1 vs. 15.9 ± 6.3; p = 0.001) and intensive care unit admissions (41.7% vs. 4.4%; p = 0.003) than the 
non-ESBL group. Multiple logistic regression analysis revealed that male gender (odds ratio = 9.2; 95%, 
confidence interval = 1.7–50.6) and healthcare facility residency (odds ratio = 15.5; 95% confidence 
interval = 2.4–98.9) were independent risk factors for ESBL-producer infections among bacteremic UTIs. 
Although the mortality rate of both groups was similar (8.3% vs. 4.4%; p = 0.403), the ESBL group had 
longer hospital stays (16.3 ± 9.3 days vs. 7.9 ± 5.2 days; p = 0.010) and higher antibiotic costs (615.1 ± 423.5 
USD vs. 252.8 ± 269.2 USD, p = 0.014).
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CONCLUSION: Male gender and healthcare facility residency are risk factors for ESBL-producer infec-
tions among patients with community-onset bacteremic UTIs. Patients with bacteremic UTIs caused by 
ESBL-EK also have prolonged hospital stays and higher antibiotic costs. Early detection of ESBLs and 
appropriate antibiotic coverage are likely to shorten hospital stays and reduce medical costs.
KEYWORDS: bacteremia, community, extended-spectrum β-lactamase, urinary tract infection
same pathogen, either E. coli or K. pneumoniae, within 
48 hours of admission. From the medical charts, we col-
lected demographic and clinical characteristics, including 
co-morbidities, clinical presentations, laboratory data, 
Acute Physiology and Chronic Health Evaluation (APACHE) 
II scores, intensive care unit (ICU) admission, duration 
of hospital stay, prior invasive procedures, prior urinary 
catheterizations, and responses to treatment.
Community-onset infections were defined as infec-
tions diagnosed within 48 hours of admission, and were 
further classified as healthcare-associated infections if the 
patient fulfilled any of the following criteria: more than 
48 hours of hospitalization within the past 90 days, receipt 
of hemodialysis, administration of intravenous medica-
tion or home wound care in the past 30 days, or residence 
in a nursing home or long-term care facility.12 If none of 
these criteria were met, the patients were classified as hav-
ing community-acquired infections. Antimicrobial ther-
apy was defined as inappropriate if no in vitro active 
antimicrobial agent at the usual recommended dose was 
administered within the first 48 hours. For infections due 
to ESBL-EK (extended-spectrum β-lactamase producing 
E. coli and K. pneumoniae species), oxyimino-β-lactams 
(such as cefuroxime, cefotaxime, ceftriaxone, ceftazidime, 
cefepime, and aztreonam) were considered inappropriate 
therapy, regardless of in vitro susceptibility.
The primary outcome in this study was mortality rate 
at 21 days after admission (calculated as the total number 
of deaths/total number of cases) in both ESBL and non-
ESBL groups. Antibiotic costs included antibiotics con-
sumed during hospitalization, and the total amount was 
calculated in United States dollars (USD).
Microbiological methods
Antimicrobial susceptibility was determined by the disk dif-
fusion method, and ESBL production was confirmed using 
Clinical and Laboratory Standards Institute criteria.4–6
Introduction
Extended-spectrum β-lactamase (ESBL)-producing Entero-
bacteriaceae were identified in the early 1980s following 
the introduction of oxyimino-β-lactam agents. Escherichia 
coli and Klebsiella pneumoniae are regarded as the predomi-
nant species of the ESBL producing Enterobacteriaceae.1,2 
E. coli and K. pneumoniae are major nosocomial pathogens 
that cause urinary tract infections (UTIs), intra-abdominal 
infections, and bacteremia.3 ESBL-producing isolates of 
E. coli or K. pneumoniae are reported to be resistant to all 
penicillins and cephalosporins as well as to aztreonam by 
the Clinical and Laboratory Standards Institute.4–6 UTIs 
are the most common infections seen in adults, and are 
treated with antibiotics. Some studies regard bacteremic 
incidence to be a marker of disease severity in UTIs.7,8 
Most studies on infections due to ESBL-producing 
Enterobacteriaceae have been performed in a hospital set-
ting, and the number of studies involving a community 
setting is limited.9–11 The aim of this study is to investigate 
the risk factors and treatment outcomes for bacteremic 
UTIs caused by E. coli and K. pneumoniae, with and without 
ESBL production.
Methods
Patients
This study was undertaken retrospectively by chart review 
and approved by the Institutional Review Board of the 
Tri-Service General Hospital (TSGHIRB Approval 
Number: 097-05-28), a 2,000-bed medical center in Taipei, 
Taiwan. We performed a search of our electronic medical 
record database for all patients with UTIs and bacteremia. 
From January 2006 to June 2008, 156 patients were diag-
nosed with bacteremic UTIs. We further screened the pa-
tients using the following criteria: adults aged ≥ 18 years 
with a concurrent bacteremia and bacteriuria due to the 
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Statistical analysis
Contingency data were analyzed using a two-tailed χ2 test or 
Fisher’s exact test. Continuous data were compared using 
Student’s t test. A p value of < 0.05 was considered signifi-
cant (two-tailed). A multiple logistic regression analysis 
with stepwise selection was performed for risk factor analy-
sis, with results presented as odds ratios with 95% confi-
dence intervals. All statistical analyses were performed using 
the Statistical Analysis System for version 9.1.3 (SAS, 
Cary, North Carolina, USA).
Results
Fifty-eight patients with community-onset bacteremic 
UTIs caused by E. coli or K. pneumoniae fulfilled the study 
criteria. Of these, 12 (20.7%) were caused by ESBL-EK and 
46 (79.3%) by non-ESBL-EK. The demographic and clinical 
characteristics of both groups are shown in Table 1. The 
most common underlying disease in both groups was dia-
betes [25.0% (3/12) and 34.8% (16/46), respectively], al-
though there was no statistical significance between the 
two groups (p = 0.230). The proportion of male patients 
was higher in the ESBL group than in the non-ESBL 
group, and was statistically significant [66.7% (8/12) vs. 
23.9% (11/46); p = 0.005]. There was no difference between 
the two groups in terms of clinical presentations such as 
fever, dysuria, frequency, and flank pain. The ESBL group 
had significantly more patients with indwelling urinary 
catheters [41.7% (5/12) vs. 6.5% (3/46); p = 0.002], patients 
from healthcare facilities [50% (6/12) vs. 8.7% (4/46); 
Table 1. Demographic and clinical characteristics of patients with community-onset bacteremic urinary tract infectionsa
Variables ESBL (n = 12) Non-ESBL (n = 46) p
Age (yr) 74.2 ± 14.3 (46–90) 72.3 ± 13.9 (37–92) 0.690
Sex, male 8 (66.7) 11 (23.9) 0.005
Underlying disease
 Diabetes 3 (25.0) 16 (34.8) 0.230
 Malignancy 0 (0)  6 (13.0) 0.231
 Chronic liver disease 1 (8.3) 0 (0) 0.207
 Heart failure 2 (16.7) 1 (2.2) 0.098
 COPD 1 (8.3) 1 (2.2) 0.334
 Renal disease 2 (16.7) 3 (6.5) 0.219
Prior antibiotic use in 30 days 1 (8.3) 5 (10.9) 0.406
Invasive procedure in 30 daysb  0 (0) 1 (2.2) 0.793
Indwelling urinary catheter 5 (41.7) 3 (6.5) 0.002
Healthcare-associated 6 (50.0) 4 (8.7) 0.001
APACHE II score 23.3 ± 7.1 (12–34) 15.9 ± 6.3 (2–38) 0.001
Clinical presentations   
 Fever 8 (66.7) 35 (76.1) 0.222
 Dysuria 2 (16.7) 17 (37.0) 0.122
 Frequency 2 (16.7) 6 (13.0) 0.323
 Flank pain 0 (0) 6 (13.3) 0.225
ICU admission 5 (41.7) 2 (4.4) 0.003
Bacteria
 E. coli 7 (58.3) 28 (60.9)
 K. pneumoniae 5 (41.7) 18 (39.1) 0.873
aData presented as mean ± standard deviation (range) or n (%); bincludes surgery or central catheter intervention. ESBL = Extended-spectrum 
β-lactamase; COPD = chronic obstructive pulmonary disease; APACHE II = Acute Physiology and Chronic Health Evaluation II; ICU = intensive 
care unit; E. coli = Escherichia coli; K. pneumoniae = Klebsiella pneumoniae.
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p = 0.001], prior ICU admissions [41.7% (5/12) vs. 4.4% 
(2/46); p = 0.003], and higher APACHE II scores (23.3 ± 7.1 vs. 
15.9 ± 6.3; p = 0.001) than the non-ESBL group.
Patients in the ESBL group were further divided into 
healthcare-associated and community-acquired groups. 
There was no statistical significance in the demographic and 
clinical characteristics between these two groups (Table 2).
The mortality rate of the ESBL group was similar to 
that of the non-ESBL group [8.3% (1/12) vs. 4.4% (2/46); 
p = 0.403]. However, the ESBL group had longer hospital 
stays (16.3 ± 9.3 days vs. 7.9 ± 5.2 days; p = 0.010), was more 
likely to receive inappropriate antibiotic treatment [75.2% 
(9/12) vs. 0% (0/46); p < 0.001], and had higher antibiotic 
costs (615.1 ± 423.5 USD vs. 252.8 ± 269.2 USD; p = 0.014) 
(Table 3). In addition, the ESBL group tended to have defer-
vescence later (3.6 ± 3.5 days vs. 1.8 ± 1.8 days; p = 0.106), al-
though the difference was not statistically significant. 
Multiple logistic regression analysis revealed that male 
gender (odds ratio = 9.2; 95% confidence interval = 1.7–
50.6) and healthcare facility residency (odds ratio = 15.5; 
95% confidence interval = 2.4–98.9) were independent risk 
factors for bacteremic UTIs caused by ESBL-EK.
Discussion
In our study, the incidence of ESBL producers among 
community-onset bacteremic UTIs caused by E. coli and 
K. pneumoniae between January 2006 and June 2008 was 
Table 2. Demographic and clinical characteristics of healthcare-associated and community-acquired bacteremic urinary tract 
infections caused by extended-spectrum β-lactamase producing Escherichia coli and Klebsiella pneumoniaea
Variables Healthcare-associated (n = 6) Community-acquired (n = 6) p
Age (yr) 78.7 ± 10.1 (59–88) 67.9 ± 17.3 (46–90) 0.297
Sex, male 4 (66.7) 4 (66.7) 0.455
Underlying disease    
 Diabetes 1 (16.7) 2 (33.3) 0.409
 Malignancy 0 (0) 0 (0) –
 Chronic liver disease 0 (0) 1 (16.7) 0.500
 Heart failure 2 (33.3) 0 (0) 0.227
 COPD 0 (0) 1 (16.7) 0.500
 Renal disease 1 (16.7) 1 (16.7) 0.546
Prior antibiotic use in 30 days 1 (16.7) 0 (0) 0.500
Invasive procedure in 30 daysb  0 (0) 0 (0) –
Indwelling urinary catheter 3 (50.0) 2 (33.3) 0.379
APACHE II score 27.3 ± 3.3 (22–32) 19.3 ± 7.8 (12–34) 0.056
Clinical presentations   
 Fever 3 (50.0) 5 (83.3) 0.242
 Dysuria 0 (0) 2 (33.3) 0.227
 Frequency 0 (0) 2 (33.3) 0.227
 Flank pain 0 (0) 0 (0) –
ICU admission 3 (50.0) 2 (33.3) 0.379
Bacteria   
 E. coli 2 (33.3) 5 (83.3)
 K. pneumoniae 4 (66.7) 1 (16.7) 0.114
aData presented as mean ± standard deviation (range) or n (%); bincludes surgery or central catheter intervention. COPD = Chronic obstructive 
pulmonary disease; APACHE II = Acute Physiology and Chronic Health Evaluation II; ICU = intensive care unit; E. coli = Escherichia coli; K. pneumo-
niae = Klebsiella pneumoniae.
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Table 3. Clinical outcomes of patients with bacteremic urinary tract infections caused by extended-spectrum β-lactamase-EK and 
non-extended-spectrum β-lactamase-EKa
 ESBL (n = 12) Non-ESBL (n = 46) p
Hospital stay (d) 16.3 ± 9.3 7.9 ± 5.2 0.010
Defervescence (d)  3.6 ± 3.5 1.8 ± 1.8 0.106
Inappropriate antibiotic treatment  9 (75.0) 0 (0) < 0.001
Mortality 1 (8.3) 2 (4.4) 0.403
Antibiotics cost (USD) 615.1 ± 423.5 252.8 ± 269.2 0.014
aData presented as mean ± standard deviation or n (%). ESBL-EK = extended-spectrum β-lactamase E.coli and K. pneumoniae; USD = United 
States dollars.
20.7% (12/58). Indeed, the community may be a reservoir for 
ESBL-producing pathogens.10,13,14 In a survey conducted 
from 2001 to 2002 to determine the incidence of ESBL-
producing Enterobacteriaceae in the stools of outpatients, 
the prevalence of ESBL carriers was found to increase from 
2.1% to 7.5%.14 In another study, the incidence of ESBL-
producing Enterobacteriaceae bacteremia from the com-
munity was 4.1%.11 The spread of multidrug-resistant 
Gram-negative bacteria in the community is a serious prob-
lem in public health. Recently, fecal carriage, intestinal col-
onization, international travel, and household member 
transmission were also determined to be contributing fac-
tors to the spread of ESBL-producing organisms.15–18 Kang 
et al asserted that 34.2% (13/28) of the cases of community-
onset ESBL-E. coli bacteremia originated from UTIs in 
South Korea.11
Worldwide, Klebsiella spp. remains the predominant or-
ganism producing ESBL. Colodner et al showed that 
K. pneumoniae infection was a risk factor for UTIs due 
to ESBL-producing bacteria in non-hospitalized patients.10 
In our study, the percentage of K. pneumoniae in both 
groups showed no statistical significance.
Rodríguez-Baño et al demonstrated that diabetes, pre-
vious antibiotic use, recurrent UTIs, previous hospital 
admission, old age, and male gender are potential risk fac-
tors for UTIs with ESBL-producing organisms in the 
community.9 Moor et al indicated that healthcare facili-
ties are significant reservoirs of ESBL in the community; 
indeed, 43% (42/98) of their cases were healthcare facility 
residents, and urine was indicated as the most common 
source (97%).19 In our study, male gender and healthcare 
facility residency were identified as independent risk factors 
for bacteremic UTIs caused by ESBL-EK. Although 50% of 
the patients in the ESBL group were healthcare-associated, 
these patients came to the hospital from the community 
and were infected with ESBL-producing bacteria. For pa-
tients admitted to the hospital with community-acquired 
UTIs, the risk factors for acquiring ESBL-producing organ-
isms should be considered before initiating treatment.
Apisarnthanarak et al studied community-onset 
ESBL-EK bloodstream infections in Thailand and found 
that UTIs were the most prevalent infections (56%). 
A higher mortality rate in ESBL patients than in non-ESBL 
patients [36% (13/36) vs. 15% (15/108)] was also noted, 
although the APACHE II scores on admission were simi-
lar in both groups (10 vs. 9).20 However, no statistical sig-
nificance with regard to the mortality rate was noted 
between the two groups in our study, even though both 
groups had higher APACHE II scores. Since the proportion 
of inappropriate antibiotic treatments was similar in both 
studies, the discrepancies in clinical outcome between our 
study and Apisarnthanarak’s report cannot be completely 
explained by antibiotic treatment alone. There must have 
been other issues relating to medical care.
In our study, the ESBL group showed a higher incidence 
of inappropriate antibiotic treatments, higher ICU admis-
sion rate, and higher APACHE II scores than the non-ESBL 
group, thereby leading to longer hospital stays and higher 
antibiotic costs. Although there are not enough comparative 
clinical data to determine the best treatment for infections 
caused by ESBL-producing bacteria, carbapenems remain 
the first choice for treatment of serious bloodstream-
associated infections.21 Clinicians should prescribe antibi-
otics that are appropriate, depending on the local prevalence 
of ESBLs and disease severity in the patients, especially for 
those who are at high risk of infection due to ESBL-EK.
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In conclusion, ESBL-EK infections are not uncommon 
in patients with community-onset bacteremic UTIs. Male 
gender and residence in a healthcare facility are indepen-
dent risk factors of ESBL-producer infections. Patients 
with ESBL-EK infections are more likely to have been 
given inappropriate antibiotics, and have longer hospital 
stay and higher antibiotic costs. Clinical practitioners 
should be well informed regarding potential risk factors 
for ESBLs and should be cautious about the antimicro-
bial agents administered to decrease the rate of treatment 
failure and reduce antibiotic costs.
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